Title:Serum Levels of Fibroblast Growth Factor 23 in People Living with HIV
Volume: 17
Issue: 3
Author(s): Yusuke Yoshino*, Kazunori Seo, Takatoshi Kitazawa and Yasuo Ota
Affiliation:
- Department of Internal Medicine, Teikyo University School of Medicine, Tokyo,Japan
Keywords:
Fibroblast Growth Factor (FGF) 23, HIV, Abacavir, Cardiovascular disease risk, Antiretroviral Treatment (ART),
Chronic Kidney Disease (CKD).
Abstract:
Background: Fibroblast growth factor (FGF) 23 is a well-known phosphaturic hormone
produced mainly by bone cells to maintain phosphate and mineral homeostasis. Serum FGF23 levels
are elevated in patients with chronic kidney disease (CKD), and elevated FGF23 might increase the
risk of cardiovascular disease (CVD). Several reports have documented an increased incidence of
risk factors for osteopenia, CKD, and CVD in people living with HIV (PLWH). However, few reports
related to FGF23 in PLWH have been published.
Methods: Male HIV patients who presented to the outpatient clinic of Teikyo University Hospital,
Tokyo, Japan, in 2015 and were treated with antiretroviral therapy (ART) for > 6 months were enrolled
in the study. In addition to serum FGF23 measurements, the clinical factors assessed included
age, ART regimens, and laboratory data. Spearman correlation and multiple regression analysis
were performed to determine factors significantly associated with FGF23.
Results: In total, 67 patients were enrolled in the present study. The median age was 43.7 years, the
median CD4 count was 529 cells/μL, and the median serum FGF23 level was 36.0 pg/mL. Based on
correlation and multiple regression analyses, serum FGF23 levels were significantly correlated with
HIV RNA > 50 copies (correlation analysis: t = 3.4259, P = 0.0011 / multiple regression analysis: P
= 0.00106) or abacavir (ABC)/lamivudine (3TC) use (t = 2.8618, P = 0.0057 / P = 0.02704).
Conclusion: Factors significantly associated with elevated serum FGF23 levels included poor virologic
control and ABC/3TC use.
